Edition:
United States

FDA Approves Merck's Keytruda As Monotherapy For Patients With Metastatic Small Cell Lung Cancer


Tuesday, 18 Jun 2019 06:45am EDT 

June 18 (Reuters) - Merck & Co Inc ::FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) AS MONOTHERAPY FOR PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY AND AT LEAST ONE OTHER PRIOR LINE OF THERAPY.MERCK & CO INC - CONTINUED APPROVAL FOR INDICATION MAY BE CONTINGENT UPON VERIFICATION AND DESCRIPTION OF CLINICAL BENEFIT IN CONFIRMATORY TRIALS..MERCK & CO INC - DECISION MARKS FIRST INDICATION FOR KEYTRUDA IN SCLC..